News and Events

Developing the
‘on’ switch for
immuno-oncology

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immuno-gene therapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.

Oncolytic immuno-gene therapy is expected to enhance the effectiveness of immune checkpoint blockade and become the second cornerstone of immune-oncology approaches, moving beyond incremental improvement in cancer treatment to help more patients overcome their disease.

Our Immulytic™ Platform

The “On-Switch” in Immuno-Oncology

Novel Therapeutics

Rapidly Advancing Clinical Programs

Experienced Team

Pioneers in Oncolytic Immuno-gene Therapy